- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04329767
A Prospective Post-Market Study to Evaluate the Clinical Utility of IRIS, a Three-dimensional (3-D) Anatomical Modeling Software for Pre-operative Surgical Planning and Intra-operative Navigation for Nephrectomy
September 28, 2023 updated by: Intuitive Surgical
This is a prospective, multi-center, post-market study to evaluate the clinical utility of IRIS, a 3D anatomical modeling software, with standard CT scans during pre-operative planning and intra-operative navigation for nephrectomy.
The study will be conducted over the course of 21-24 months and enroll approximately 60-120 subjects.
Study Overview
Study Type
Observational
Enrollment (Actual)
122
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Edison, New Jersey, United States, 08837
- Hackensack University Medical Center
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Subjects with kidney cancer who will undergo robotic-assisted partial or robotic-assisted radical nephrectomy.
Description
Inclusion Criteria:
- Subject is 18 years or older
- Subject is undergoing robotic-assisted partial or robotic-assisted radical nephrectomy being performed by participating surgeon
- Subjects who has had or plan to have a CT scan (with IV contrast medium)
Exclusion Criteria:
- Subject has a solitary or horseshoe kidney
- Subject has more than two masses in the applicable kidney requiring multiple partial nephrectomies on the same kidney
- Subject with prior surgery (ex: partial nephrectomy etc.) on the affected kidney excluding endoscopic kidney stone surgery
- Subject with renal vein tumor thrombus
- Subjects planned to have a bilateral operation (ex: bilateral partial nephrectomies planned at the same time)
- Metastatic disease with life expectancy of less than 1 year
- Pregnant or suspect pregnancy
- Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent
- Subject belonging to other vulnerable population, e.g, prisoner or ward of the state
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
IRIS Arm
Utilize the CT scan along with the IRIS 3D model preoperatively and intraoperatively
|
Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans.
It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
|
|
CT Arm
Utilize only the standard 2D CT scan preoperatively and intraoperatively
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical utility of IRIS 3D model with CT scans during Intra-Operative navigation
Time Frame: Intra-operative
|
|
Intra-operative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical utility of IRIS 3D model with CT scans during preoperative surgical planning
Time Frame: Preoperative
|
|
Preoperative
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 18, 2020
Primary Completion (Actual)
February 3, 2023
Study Completion (Actual)
August 31, 2023
Study Registration Dates
First Submitted
March 30, 2020
First Submitted That Met QC Criteria
March 30, 2020
First Posted (Actual)
April 1, 2020
Study Record Updates
Last Update Posted (Actual)
September 29, 2023
Last Update Submitted That Met QC Criteria
September 28, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISI-IRIS-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Cancer
-
Guliz OzgunBritish Columbia Cancer AgencyNot yet recruiting
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnKidney/Urinary Cancer
-
Tianjin Medical University Second HospitalRecruiting
-
Cedars-Sinai Medical CenterRecruitingProstate Cancer Stage II | Prostate Cancer Stage I | Bladder Cancer Stage II | Kidney Cancer Stage IUnited States
-
Tianjin Medical University Second HospitalRecruiting
-
Intuitive SurgicalCompleted
-
Dana-Farber Cancer InstituteCompletedKidney Cancer | Prostate Cancer | Genitourinary CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedKidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IVUnited States
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
Clinical Trials on IRIS 1.0
-
Intelligent Medical Implants GmbHUnknownRetinitis Pigmentosa | Choroideremia | Cone-Rod Dystrophy
-
University of Missouri-ColumbiaCompleted
-
Universitaire Ziekenhuizen KU LeuvenTerminated
-
Duke UniversityEli Lilly and Company; Bayer; Boehringer IngelheimRecruitingType 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease(CKD) | Type 2 DMUnited States
-
PainQx, IncNational Institute on Drug Abuse (NIDA)CompletedChronic PainUnited States
-
Clinical Research Consultants, Inc.HumanOptics AGRecruitingFull Aniridia | Partial AniridiaUnited States
-
Assiut UniversityCompleted
-
Duke UniversityEli Lilly and Company; Bayer; Boehringer IngelheimRecruitingType 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease(CKD) | Type 2 DMUnited States
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompleted
-
Boston Scientific CorporationCompletedMitral Valve InsufficiencyBrazil, Paraguay